The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
FDA Approves Frontline Obinutuzumab for CLL
November 1st 2013The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.
Large-Scale Analysis Confirms Superiority of Hyperfractionation in HNSCC
October 29th 2013Hyperfractionated radiotherapy improved overall survival rates compared to standard and accelerated radiotherapy when administered without concomitant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Pre-Chemo Trial of Enzalutamide Halted After Meeting Endpoints
October 22nd 2013The phase III PREVAIL trial of enzalutamide in chemotherapy-naïve patients with advanced prostate cancer has been stopped early after meeting its co-primary endpoints of overall survival and radiographic progression-free survival
Vemurafenib Demonstrates Antitumor Activity in Papillary Thyroid Cancer
October 18th 2013In a phase II clinical trial, the BRAF inhibitor vemurafenib demonstrated antitumor activity in patients with BRAFV600E-mutated papillary thyroid cancer who were either TKI treatment naïve or had received prior TKI treatments.
National Cancer Institute Awards Leukemia Reseachers at Siteman $26 Million
October 7th 2013The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.